# ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

> **NCT06656494** · PHASE1 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 266 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** ICP-248
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06656494
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2027-06
- **Final completion:** 2028-01
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06656494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06656494, "ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06656494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*